SYRE
NASDAQSpyre Therapeutics Inc.
News25/Ratings11
News · 26 weeks69+1000%
2026-03-012026-08-23
Mix3690d
- Insider18(50%)
- Other10(28%)
- SEC Filings7(19%)
- Analyst1(3%)
Latest news
25 items- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) SPY072 was well tolerated with rates of adverse events comparable to placebo Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.SCHEDULE 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.SCHEDULE 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
- INSIDERDirector Albers Jeffrey W. exercised 5,000 shares at a strike of $10.39 and sold $2,404,190 worth of shares (23,000 units at $104.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis SuppurativaSPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT trial designed to provide clinical proof-of-concept for TL1A and IL-17A/F inhibition in Hidradenitis Suppurativa; site activation has begun with topline Week 16 HiSCR75 data planned for late 2027 or early 2028 WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units ("RSUs") to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equ
- INSIDERChief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $716,771 worth of shares (7,500 units at $95.57) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,432,705 worth of shares (15,000 units at $95.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 567,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- SECSEC Form 10-Q filed by Spyre Therapeutics Inc.10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
- ANALYSTSpyre Therapeutics downgraded by Wolfe ResearchWolfe Research downgraded Spyre Therapeutics from Outperform to Peer Perform
- INSIDERChief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units ("RSUs") to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equi
- INSIDERChief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SECSEC Form S-3ASR filed by Spyre Therapeutics Inc.S-3ASR - Spyre Therapeutics, Inc. (0001636282) (Filer)
- INSIDERDirector Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERDirector Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsSPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 33% and endoscopic improvement of 42% SPY002 was well tolerated with a safety profile consistent with the TL1A class SPY002 Phase 2 results delivered within one year of Phase 1 results, highlighting continued operational excellence; on track for multiple additional readouts this year WALTHAM, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-gener
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018
- INSIDERChief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
SYRE FAQ
6 questionsWhere does SYRE stock trade?
Spyre Therapeutics Inc. (SYRE) is listed on NASDAQ.What sector and industry is SYRE in?
Spyre Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spyre Therapeutics Inc. go public?
Spyre Therapeutics Inc. (SYRE) completed its IPO in 2016.What are analysts saying about SYRE?
Spyre Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-07-28. Recent price targets range from $2700.00 to $4500.00.What companies are similar to SYRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SYRE side-by-side with any of them on Quantisnow.How can I track SYRE on Quantisnow?
Quantisnow aggregates Spyre Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYRE to receive live email and push alerts on every new disclosure.